Newsletter

039200 - Oscotec, Inc.

039200 Summary
Biopharma
Stock Price & Overview
₩36,600 +700 (+1.95%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩36,600  ≈ US$26  ·  Market cap ₩1.4tn (≈ $1.0bn)

039200 Quarterly Results

Quarter ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
2026 Q252.6+425.6%38.773.5%—40.8₩1,065
2026 Q13.6+88.4%-10.0-273.8%—-5.0₩-130
2025 Q478.9+3,279.3%61.477.8%—64.0₩1,673
2025 Q38.9-69.2%-0.4-4.2%-101.9%0.6₩17
2025 Q210.0+544.7%-0.6-6.3%—-2.5₩-65
2025 Q11.9+82.3%-8.3-429.8%—-7.8₩-203
2024 Q42.3—-7.0-301.2%—-6.9₩-179
2024 Q329.1—19.667.6%—19.3₩503
Three-month figures from DART consolidated statements. Q4 is the annual figure less the nine-month cumulative. EPS is net income over today's share count, so buybacks and issuance move earlier quarters. YoY compares with the same quarter a year earlier and is blank when that quarter was a loss.

039200 Annual Results

Full statements »
Fiscal year ₩bnRevenueYoYOperating incomeMarginYoYNet incomeEPS
FY202599.8+193.6%52.152.2%—54.4₩1,422
FY202434.0+586.9%-2.7-8.0%—-1.6₩-42
FY20235.0-2.2%-32.7-659.6%—-28.5₩-745
FY20225.1+29.7%-28.6-565.7%—-27.8₩-726
FY20213.9-91.0%-28.1-719.9%-1,877.8%-28.6₩-747
FY202043.5+895.1%1.63.6%—-2.0₩-53

039200 Next Report

The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.

Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.

039200 Earnings Filings

All filings »
DART

Half-Year Report

Periodic08/14/26title translated
DART

Quarterly Report

Periodic05/14/26title translated

How Korean earnings differ from US earnings

  • No quarterly guidance culture. Most KRX companies give no EPS or revenue guidance; the preliminary filing is the first number the market sees, and there is no consensus beat/miss ritual built around it.
  • Preliminary first, then the report. The 잠정실적 filing carries revenue and operating profit; net income and the balance sheet come with the full report weeks later.
  • Consolidated is the headline. Korean companies report consolidated (K-IFRS) and separate (parent-only) figures; kstock uses consolidated unless the page says otherwise.
  • Fiscal years end in December for almost every listed company, so Q4 is derived: the annual figure less the nine-month cumulative.

Similar to 039200

SymbolLast Price
140410Mezzion Pharma Co., Ltd.₩65,000
+0.0%
068760Celltrion Pharm, Inc.₩40,850
+0.0%
007390Naturecell Co., Ltd.₩23,950
+0.2%
006280GC Biopharma Corp.₩127,600
+0.5%
950160Kolon Tissue Gene, Inc.₩17,100
+1.1%
069620Daewoong Pharma₩116,100
+1.1%
290650L & C BIO Co., Ltd.₩47,900
-1.4%
127120JS Link₩33,600
+12.4%
475830Orum Therapeutics, Inc.₩55,900
+2.6%
195940HK inno.N Corporation₩42,050
+0.7%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.